Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doripenem - Shionogi

Drug Profile

Doripenem - Shionogi

Alternative Names: Doribax; Doripenem hydrate; Finibax IV Solution; S-4661

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Janssen Research & Development; Ortho-McNeil; Shionogi
  • Class Anti-infectives; Antibacterials; Carbapenems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Respiratory tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Intra-abdominal infections; Meningococcal infections; Nosocomial pneumonia; Paediatric infections; Respiratory tract infections; Urinary tract infections; Ventilator associated pneumonia
  • Discontinued Bacterial infections; Pneumonia

Most Recent Events

  • 26 Aug 2022 Discontinued - Preregistration for Ventilator-associated-pneumonia in USA (IV)
  • 12 Aug 2013 Discontinued - Phase-III for Ventilator-associated-pneumonia in Australia, Canada, Guatemala, India, Israel, Mexico, Philippines, Russia, South Africa,Thailand, Turkey and Ukraine (IV)
  • 31 Jul 2013 Phase-III clinical trials in Intra-abdominal infections (in children and adolescents, Complicated) in India prior to July 2013 (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top